- Home
- MUA vs TBPH Comparison
MUA vs TBPH Comparison
Compare MUA & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUA
- TBPH
- Stock Information
- Founded
- MUA 1993
- TBPH 2013
- Country
- MUA United States
- TBPH United States
- Employees
- MUA N/A
- TBPH N/A
- Industry
- MUA Investment Bankers/Brokers/Service
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- MUA Finance
- TBPH Health Care
- Exchange
- MUA Nasdaq
- TBPH Nasdaq
- Market Cap
- MUA 396.8M
- TBPH 464.5M
- IPO Year
- MUA N/A
- TBPH N/A
- Fundamental
- Price
- MUA $10.18
- TBPH $10.63
- Analyst Decision
- MUA
- TBPH Buy
- Analyst Count
- MUA 0
- TBPH 4
- Target Price
- MUA N/A
- TBPH $14.50
- AVG Volume (30 Days)
- MUA 92.6K
- TBPH 319.2K
- Earning Date
- MUA 01-01-0001
- TBPH 08-04-2025
- Dividend Yield
- MUA 4.84%
- TBPH N/A
- EPS Growth
- MUA N/A
- TBPH N/A
- EPS
- MUA N/A
- TBPH N/A
- Revenue
- MUA N/A
- TBPH $65,266,000.00
- Revenue This Year
- MUA N/A
- TBPH $43.53
- Revenue Next Year
- MUA N/A
- TBPH N/A
- P/E Ratio
- MUA N/A
- TBPH N/A
- Revenue Growth
- MUA N/A
- TBPH 6.11
- 52 Week Low
- MUA $8.61
- TBPH $7.44
- 52 Week High
- MUA $11.43
- TBPH $11.82
- Technical
- Relative Strength Index (RSI)
- MUA 44.63
- TBPH 57.46
- Support Level
- MUA $10.13
- TBPH $10.42
- Resistance Level
- MUA $10.29
- TBPH $11.00
- Average True Range (ATR)
- MUA 0.09
- TBPH 0.42
- MACD
- MUA 0.00
- TBPH -0.03
- Stochastic Oscillator
- MUA 25.00
- TBPH 35.50
About MUA Blackrock MuniAssets Fund Inc
Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).